Skip to main content
. 2022 May 13;35(1):ivac134. doi: 10.1093/icvts/ivac134

Table 1:

Patient characteristics

Original data
Propensity matched
OPCABG RA-CABG P-value SMD OPCABG RA-CABG P-value SMD
(N = 194) (N = 107) (N = 102) (N = 102)
Age, median (IQR) 67.7 (10.2) 65.3 (8.6) 0.04 0.255 66.2 (10.4) 65.3 (8.7) 0.47 0.102
Logistic EuroSCORE I, median (IQR) 3.3 (2.8) 2.94 (3.4) 0.32 0.118 2.9 (2.7) 2.7 (2.3) 0.45 0.106
eGFR, median (IQR) 70.3 (20.1) 75.4 (17.8) 0.03 0.273 73.4 (19.2) 75.1 (17.8) 0.52 0.089
Female gender, N (%) 42 (21.6) 30 (28.0) 0.27 0.148 24 (23.5) 27 (26.5) 0.75 0.068
Diabetes, N (%) 0.06 0.295 0.92 0.058
Type 1 3 (1.5) 4 (3.7) 3 (2.9) 4 (3.9)
Type 2 50 (25.8) 16 (15.0) 17 (16.7) 16 (15.7)
No diabetes 141 (72.7) 87 (81.3) 82 (80.4) 82 (80.4)
Hypertension, N (%) 117 (60.3) 56 (52.3) 0.22 0.161 67 (65.7) 54 (52.9) 0.09 0.262
Recent myocardial infarction, N (%) 55 (28.4) 20 (18.7) 0.09 0.229 18 (17.6) 19 (18.6) 1.00 0.025
Atrial fibrillation, N (%) 8 (4.1%) 3 (2.8%) 0.79 0.072 3 (2.9%) 2 (2.0%) 1.00 0.063
Chronic pulmonary disease, N (%) 14 (7.2) 15 (14.0) 0.09 0.222 12 (11.8) 12 (11.8) 1.00 <0.001
Extracardiac arteriopathy, N (%) 11 (5.7) 8 (7.5) 0.71 0.073 4 (3.9) 7 (6.9) 0.54 0.130
Neurological dysfunction, N (%) 1 (0.5) 5 (4.7) 0.04 0.264 1 (1.0) 3 (2.9) 0.61 0.142
LVEF = 30-50%, N (%) 41 (21.1) 25 (23.4) 0.76 0.054 21 (20.6) 23 (22.5) 0.87 0.048
Aspirin, N (%) 159 (82.0) 85 (79.4) 0.70 0.064 87 (85.3) 81 (79.4) 0.36 0.155
Clopidogrel, N (%) 86 (44.3) 29 (27.1) 0.01 0.365 25 (24.5) 28 (27.5) 0.75 0.067
Ticagrelor, N (%) 5 (2.6) 4 (3.7) 0.83 0.066 2 (2.0) 4 (3.9) 0.68 0.116
Coumadin, N (%) 11 (5.7) 6 (5.6) 1.00 0.003 3 (2.9) 5 (4.9) 0.72 0.101

CABG: coronary artery bypass grafting; eGFR: estimated glomerular filtration rate; IQR: interquartile range; LVEF: left ventricular ejection fraction; OPCABG: conventional off-pump CABG; RA-CABG: robot-assisted CABG; SMD: standardized mean difference.